Westlake Village BioPartners
Venture capitalLos Angeles · Pre-Seed–Series A · 11 people tracked
Investment thesis
Westlake BioPartners believes that exceptional entrepreneurs and people-first support are critical to bringing breakthrough medicines to market. The firm invests in life science companies from ideation through clinical and commercial stages, providing concentrated portfolio companies with equal access to capital, innovation resources, and a symbiotic entrepreneurial ecosystem. By combining hands-on guidance with deep Los Angeles biotech community connections, the firm aims to address unmet patient needs through life-changing treatments.
Source: firm website, verified Jul 21, 2026.
Team · 11 people
from the firm's website
Physician and veteran biotech investor who has incubated and invested in over 40 biotech companies since 2005. Previously a General Partner at Kleiner Perkins and held leadership roles at Bristol-Myers Squibb, Merck Research Laboratories, and Amgen where she served as chief medical officer. Sits on public company boards including Acelyrin, Kyverna, Progyny, Sagimet, and Vera.
Investment and translational research professional with over 15 years of biotech investing and company formation experience. Previously a Partner at 5AM Ventures and held positions at Versant Ventures, Split Rock Partners, and PTV Healthcare Capital. Holds a Ph.D. in Bioengineering from Rice University and B.S.E. in Biomedical Engineering from the University of Iowa.
Biotech investor with experience across multiple therapeutic areas and modalities. Previously a Partner at 5AM Ventures where she invested in and served on boards of numerous companies. Kauffman Fellow and serves on boards of Nucleate and formerly Biotech Connection Bay Area. Completed postdoctoral fellowship at Genentech with Ph.D. in Biological Sciences from UC San Diego.
Finance professional managing accounting, finance and operations at the firm. Previously worked on accounting teams at PwC and The Walt Disney Company. Licensed CPA with M.S. and B.S. in Accounting from the University of Denver.
Finance and operations leader managing accounting, finance and strategic initiatives at the firm. Brings 10 years of accounting experience from public accounting firms KPMG and Crowe Horwath LLP, plus private equity background from ICONIQ Capital. Licensed CPA with B.B.A. in Accounting and Finance from Sonoma State University.
Pharmaceutical development professional with 20 years at Amgen where he rose to Vice President of Translational Medicine and Vice President of Pharmacokinetics and Drug Metabolism. Has served as founding CEO of Capsida Biotherapeutics and interim CEO of Latigo Biotherapeutics. Holds PharmD from Wayne State University and clinical pharmacology fellowship from Henry Ford Hospital.
Legal and operational expert with over 15 years in venture capital. Previously served as Chief Legal Officer and COO at Section32 and General Counsel at GV (Google Ventures). Also held M&A counsel position at Google and associate role at Wilson, Sonsini, Goodrich and Rosati.
Operations professional supporting firm and portfolio company development. Previously spent over 20 years at Amgen as an executive administrator with experience leading teams across multiple functional areas. Holds B.A. in Sociology with business minor from Cal State Dominguez Hills.
Investment professional supporting new deals and portfolio companies. Previously Senior Director of Translational Biology at Novome Biotechnologies focused on microbial-based therapeutics. Completed postdoctoral fellowship at UC Berkeley with Ph.D. in Microbiology and Immunology from Stanford University School of Medicine.
What they invest in
from 7 of 16 portfolio companiesBiotech ×7Medical Devices ×5Digital Health ×3Healthtech ×3AI & Machine Learning ×1Deep Tech ×1
HQs:United States×3
Investments · 16 tracked
founders shown can be your intro pathCapsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids. The company targets both central nervous system and ophthalmology conditions across all ages.
BiotechDeep TechDigital HealthMedical Devices
Viviana GradinaruNick Goeden, Ph.D.(Co-founder)Nicholas Flytzanis(Co-founder)
An immunotherapy company developing next-generation, transformative therapies for broad patient populations.
3T Biosciences develops TCR-based immunotherapies for cancer using a proprietary platform that combines machine-learning algorithms with immunological research to identify and validate T cell receptor targets. The company creates therapeutic treatments targeting cancer and other difficult-to-treat diseases.
AI & Machine LearningBiotechHealthtechMedical DevicesSouth San Francisco, US
K. Christopher Garcia
Clinical stage company developing a small molecule pan-ROCK inhibitor targeting pulmonary and fibrotic indications.
AllRock Bio develops novel drug therapies targeting pulmonary hypertension and fibrotic lung diseases, with a lead program focused on ROCK inhibitors for pulmonary arterial hypertension and related conditions. The company is dedicated to accelerating clinical development and bringing life-saving treatments to patients worldwide.
BiotechDigital HealthMedical Devices
A clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer.
Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors. The company uses computational and engineering approaches to create cancer medicines.
BiotechHealthtechMedical Devices
A next-generation RNA medicines company that is advancing a novel platform to enable precision targeting of RNA therapeutics for a variety of kidney diseases.
Borealis develops RNA medicines to treat kidney diseases. The company was founded by the team behind Chinook Therapeutics, which Novartis acquired in 2023, and focuses on kidney disease indications with unmet medical need.
BiotechDigital Health
A clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.
A patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases.
A patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.
Biotech
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment. The company explores and validates novel drug targets with a focus on breakthrough therapies addressing underlying disease pathology.
BiotechHealthtechMedical Devices
Board seats · per SEC filings
what is this? ⓘ$35.3M raise · filed Nov 2025 · via David G. Allison, Mira G. Chaurushiya
Inferred from directors named on each company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Westlake Village BioPartners invest at?
- Westlake Village BioPartners invests at the Pre-Seed, Seed, Series A stages.
- What sectors does Westlake Village BioPartners focus on?
- Westlake Village BioPartners focuses on Biotech, Digital Health, Medical Devices.
- Where is Westlake Village BioPartners located?
- Westlake Village BioPartners is headquartered in Los Angeles, US.
Images
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
Breyer Capital is a venture capital firm that invests in high-impact entrepreneurs with a strategic focus on companies leveraging artificial intelligence and machine learning to transform technology sectors globally.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
Innovestor is a Finnish investment manager that operates across venture capital, real estate, and energy storage sectors. The firm invests in early-stage technology and life science startups, energy-efficient commercial real estate, and battery storage and solar solutions. Innovestor also provides corporate venturing advisory services.
A European investment firm established in 2016 by former Index Ventures life sciences professionals with over 20 years of experience in drug discovery and therapeutic development for unmet medical needs.